EOLS logo

Evolus (EOLS)

Profile

Full Name

Evolus, Inc.

Ticker Symbol

EOLS

Exchange

NASDAQ

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Country

United States

IPO

February 8, 2018

Indexes

Not included

Website

http://www.evolus.com

Employees

332

Key Details

Price

$9.99(+4.72%)

Market cap

$635.23M(Small cap)

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$266.27M(+31.76% YoY)

Annual EPS

-$0.81(+25.00% YoY)

PE ratio

-

Next earnings date

May 7, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$9.99
EOLS price is $9.99

30-Day Relative Volume

1.10
EOLS 30-day relative volume is 1.10

Price Performance

Price Today change

+4.72%
EOLS price is up +4.72% today

Price YTD change

-9.51%
EOLS price is down -9.51% since January 1st

Price 1-year change

-17.37%
EOLS price is down -17.37% year-on-year

Price 3-year change

-11.44%
EOLS price is down -11.44% over the past 3 years

Price Range

Price All-time high

$39.50
EOLS price is currently -74.71% below its historical high of $39.50

Price 3-year low

$6.51
EOLS price is currently +53.46% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$635.23M
EOLS market capitalization is $635.23 million

Market cap 3-year change

+0.48%
EOLS market capitalization is up +0.48% over the past 3 years

Market cap All-time high

$1.12B
EOLS market capitalization is currently -43.26% below its historical high of $1.12 billion

Market cap sector rank

72.39%
EOLS market capitalization is higher than 72.39% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

+1.59%
EOLS shares outstanding is up +1.59% year-on-year

Shares Outstanding 3-Year Change

+13.46%
EOLS shares outstanding is up +13.46% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

1.15
EOLS beta is 1.15

200-day SMA

$13.53
EOLS price is currently -26.19% below its 200-day simple moving average

50-day SMA

$13.02
EOLS price is currently -23.30% below its 50-day simple moving average

RSI

30.08
EOLS 14-day relative strength index is 30.08

Volume

1.10
EOLS 30-day relative volume is 1.10

ATR

$0.91
EOLS average true range is $0.91

10-day Historical Volatility

97.06%
EOLS 10-day historical volatility is 97.06%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$266.27M
EOLS annual revenue is $266.27 million

Revenue Analysts estimate

$351.87M
EOLS annual revenue is currently -24.33% lower than the consensus analysts' forecast

Revenue 1-year change

+31.76%
EOLS annual revenue is up +31.76% year-on-year

Revenue Sector rank

67.41%
EOLS annual revenue is higher than 67.41% of companies in Healthcare sector

EPS

EPS

-$0.81
EOLS annual earnings per share is -$0.81

EPS Analysts estimate

-$0.06
EOLS annual earnings per share is currently +1250.00% higher than the consensus analysts' forecast

EPS 1-year change

+25%
EOLS annual earnings per share is up +25% year-on-year

EPS Sector rank

60.94%
EOLS annual earnings per share is higher than 60.94% of companies in Healthcare sector

Profit

Gross profit

$182.30M
EOLS annual gross profit is $182.30 million

Gross margin

68.46%
EOLS annual gross profit margin is 68.46%

Operating profit

-$27.23M
EOLS annual operating income is -$27.23 million

Operating margin

-10.23%
EOLS annual operating profit margin is -10.23%

Net income

-$50.42M
EOLS annual net profit is -$50.42 million

Net margin

-18.94%
EOLS annual net profit margin is -18.94%

Expenses

Total expenses

$293.51M
EOLS annual total expenses is $293.51 million

Operating expenses

$209.54M
EOLS annual total operating expenses is $209.54 million

Cost of goods sold

$83.97M
EOLS annual cost of goods sold is $83.97 million

Selling, general & administrative expenses

$198.03M
EOLS annual SGA is $198.03 million

Depreciation and amortization

$6.02M
EOLS annual depreciation & amortization is $6.02 million

Interest expense

$18.73M
EOLS annual interest expense is $18.73 million

Income tax

$664.00K
EOLS annual income tax is $664.00 thousand

EBIT & EBITDA

EBIT

-$31.02M
EOLS annual earnings before interest & taxes is -$31.02 million

EBITDA

-$25.00M
EOLS annual EBITDA is -$25.00 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$232.57M
EOLS annual total assets is $232.57 million

Non current assets

$81.23M
EOLS annual long term assets is $81.23 million

Current assets

$151.34M
EOLS annual total current assets is $151.34 million

Cash and cash equivalents

$86.95M
EOLS annual cash & cash equivalents is $86.95 million

Accounts receivable

$47.68M
EOLS annual accounts receivable is $47.68 million

Inventory

$12.16M
EOLS annual inventory is $12.16 million

Liabilities

Total liabilities

$227.05M
EOLS annual total liabilities is $227.05 million

Long term liabilities

$164.09M
EOLS annual total long term liabilities is $164.09 million

Current liabilities

$62.96M
EOLS annual total current liabilities is $62.96 million

Accounts payable

$9.24M
EOLS annual accounts payable is $9.24 million

Debt

Total debt

$129.98M
EOLS annual total debt is $129.98 million

Total debt 1-year change

+2.71%
EOLS annual total debt is up +2.71% year-on-year

Long term debt

$128.26M
EOLS annual long term debt is $128.26 million

Short term debt

$1.72M
EOLS annual short term debt is $1.72 million

Equity & Capital

Shareholders equity

$5.52M
EOLS annual stockholders equity is $5.52 million

Book value

$5.52M
EOLS annual book value is $5.52 million

Retained earnings

-$609.40M
EOLS annual retained earnings is -$609.40 million

Working capital

$88.38M
EOLS annual working capital is $88.38 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

-$18.00M
EOLS annual cash flow from operations is -$18.00 million

Cash from operations 1-year change

+47.07%
EOLS annual cash flow from operations is up +47.07% year-on-year

Cash from investing

-$4.82M
EOLS annual cash flow from investing activities is -$4.82 million

Cash from investing 1-year change

-196.44%
EOLS annual cash flow from investing activities is down -196.44% year-on-year

Cash from financing

$47.41M
EOLS annual cash flow from financing activities is $47.41 million

Cash from financing 1-year change

+6.21%
EOLS annual cash flow from financing activities is up +6.21% year-on-year

CAPEX

CAPEX

$4.82M
EOLS annual capital expenditures is $4.82 million

CAPEX 1-year change

+196.44%
EOLS annual capital expenditures is up +196.44% year-on-year

Free Cash Flow

Free cash flow

-$22.82M
EOLS annual free cash flow is -$22.82 million

Free cash flow 1-year change

+35.96%
EOLS annual free cash flow is up +35.96% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

68.46%
EOLS annual gross profit margin is 68.46%

Operating margin

-10.23%
EOLS annual operating profit margin is -10.23%

Net margin

-18.94%
EOLS annual net profit margin is -18.94%

ROA & ROE

ROA

-23.92%
EOLS annual return on assets is -23.92%

ROE

-913.07%
EOLS annual return on equity is -913.07%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

-
EOLS price to earnings ratio value is unknown

PE ratio Sector rank

-
EOLS price to earnings ratio is unknown

PB Ratio

PB ratio

115.04
EOLS price to book ratio is 115.04

PB ratio Sector rank

99.59%
EOLS price to book ratio is higher than 99.59% of companies in Healthcare sector

PS Ratio

PS ratio

2.39
EOLS price to sales ratio is 2.39

PS ratio Sector rank

45.77%
EOLS price to sales ratio is higher than 45.77% of companies in Healthcare sector

Enterprise value

Enterprise value

$678.26M
EOLS enterprise value is $678.26 million

Enterprise value Sector rank

72.25%
EOLS enterprise value is higher than 72.25% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-27.13
EOLS EV/EBITDA is -27.13

EV/EBITDA Sector rank

4.78%
EOLS EV/EBITDA is higher than 4.78% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

2.40
EOLS annual current ratio is 2.40

Quick ratio

2.21
EOLS annual quick ratio is 2.21

Leverage

Debt to equity

22.00
EOLS annual debt to equity ratio is 22.00

Interest coverage ratio

-1.66
EOLS annual interest coverage ratio is -1.66

Risk & Stability

Piotroski F-Score

3
EOLS piotroski f-score is 3

Altman Z-Score

-0.83
EOLS altman z-score is -0.83

Analyst ratings

Recent major analysts updates

Apr 10, 25 HC Wainwright & Co.
Buy
Apr 9, 25 Needham
Buy
Mar 5, 25 Needham
Buy
Mar 5, 25 HC Wainwright & Co.
Buy
Mar 5, 25 Barclays
Overweight
Feb 14, 25 HC Wainwright & Co.
Buy
Jan 27, 25 Barclays
Overweight
Jan 22, 25 HC Wainwright & Co.
Buy
Jan 21, 25 Needham
Buy
Nov 7, 24 HC Wainwright & Co.
Buy

Institutional Ownership

Similar stocks

XNCR logo
Xencor (XNCR)
ABUS logo
Arbutus Biopharma (ABUS)
PRAX logo
Praxis Precision Medicines (PRAX)
BFLY logo
Butterfly Network (BFLY)
IMNM logo
Immunome (IMNM)
AVBP logo
ArriVent BioPharma (AVBP)
Bicara Therapeutics (BCAX)
FLGT logo
Fulgent Genetics (FLGT)
AVNS logo
Avanos Medical (AVNS)
  • What is the ticker symbol for Evolus?
  • Does Evolus pay dividends?
  • What sector is Evolus in?
  • What industry is Evolus in?
  • What country is Evolus based in?
  • When did Evolus go public?
  • Is Evolus in the S&P 500?
  • Is Evolus in the NASDAQ 100?
  • Is Evolus in the Dow Jones?
  • When was Evolus's last earnings report?
  • When does Evolus report earnings?
  • Should I buy Evolus stock now?

What is the ticker symbol for Evolus?

The ticker symbol for Evolus is NASDAQ:EOLS

Does Evolus pay dividends?

No, Evolus does not pay dividends

What sector is Evolus in?

Evolus is in the Healthcare sector

What industry is Evolus in?

Evolus is in the Drug Manufacturers - Specialty & Generic industry

What country is Evolus based in?

Evolus is headquartered in United States

When did Evolus go public?

Evolus's initial public offering (IPO) was on February 8, 2018

Is Evolus in the S&P 500?

No, Evolus is not included in the S&P 500 index

Is Evolus in the NASDAQ 100?

No, Evolus is not included in the NASDAQ 100 index

Is Evolus in the Dow Jones?

No, Evolus is not included in the Dow Jones index

When was Evolus's last earnings report?

Evolus's most recent earnings report was on Mar 4, 2025

When does Evolus report earnings?

The next expected earnings date for Evolus is May 7, 2025

Should I buy Evolus stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page